Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effect of Linagliptin on Arterial 18F-Fluorodeoxyglucose Positron Emission Tomography Uptake: A Randomized Controlled Trial (RELEASE).

× No keyword cloud information.

4 in total

1. Is having a sweetheart enough to survive?

Authors: Samia Massalha; Riemer H J A Slart
Journal: J Nucl Cardiol Date: 2018-09-06 Impact factor: 5.952

2. Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy.

Authors: Kuan-Yin Ko; Shan-Ying Wang; Ruoh-Fang Yen; Yu-Chien Shiau; Jung-Cheng Hsu; Hao-Yuan Tsai; Chien-Lin Lee; Kuan-Ming Chiu; Yen-Wen Wu
Journal: J Nucl Cardiol Date: 2018-08-14 Impact factor: 5.952

3. [¹⁸F]FDG and [¹⁸F]NaF as PET markers of systemic atherosclerosis progression: A longitudinal descriptive imaging study in patients with type 2 diabetes mellitus.

Authors: M Reijrink; S A de Boer; C A Te Velde-Keyzer; J K E Sluiter; R A Pol; H J L Heerspink; M J W Greuter; J L Hillebrands; D J Mulder; R H J A Slart
Journal: J Nucl Cardiol Date: 2021-09-13 Impact factor: 3.872

4. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA^®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Authors: Julio Rosenstock; Vlado Perkovic; John H Alexander; Mark E Cooper; Nikolaus Marx; Michael J Pencina; Robert D Toto; Christoph Wanner; Bernard Zinman; David Baanstra; Egon Pfarr; Michaela Mattheus; Uli C Broedl; Hans-Juergen Woerle; Jyothis T George; Maximilian von Eynatten; Darren K McGuire
Journal: Cardiovasc Diabetol Date: 2018-03-14 Impact factor: 9.951

4 in total

Effect of Linagliptin on Arterial 18F-Fluorodeoxyglucose Positron Emission Tomography Uptake: A Randomized Controlled Trial (RELEASE).

1. Is having a sweetheart enough to survive?

2. Clinical significance of quantitative assessment of glucose utilization in patients with ischemic cardiomyopathy.

3. [18F]FDG and [18F]NaF as PET markers of systemic atherosclerosis progression: A longitudinal descriptive imaging study in patients with type 2 diabetes mellitus.

4. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.

Effect of Linagliptin on Arterial ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography Uptake: A Randomized Controlled Trial (RELEASE).

3. [¹⁸F]FDG and [¹⁸F]NaF as PET markers of systemic atherosclerosis progression: A longitudinal descriptive imaging study in patients with type 2 diabetes mellitus.

4. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA^®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.